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Short summary: A study of men who have sex with men with proctitis revealed that 
Mycoplasma genitalium (31% [25-38]) was commonly detected, and microbiological cure 
with azithromycin was low (35% [22-50]). 
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ABSTRACT 
Background 
We report clinical characteristics of proctitis caused solely by Mycoplasma genitalium(MG), 
compared with chlamydia and gonococcus.  We determined the proportions cured with first-
line (azithromycin) and second-line antimicrobials (moxifloxacin, pristinamycin).   
Methods 
166 patients attending Melbourne Sexual Health Centre from 2012 to 2016 with symptoms of 
proctitis were tested for MG, Chlamydia trachomatis and Neisseria gonorrhoeae.  
Demographic characteristics, sexual behaviours, clinical symptoms and signs were recorded.  
Multinomial multivariable logistic regression was used to test for significant differences in 
symptoms and signs for the pathogens detected. 
Results 
Seventeen percent of men had MG (95% confidence interval [12-24]), 21% chlamydia [15-
27], and 40% gonococcal monoinfection [32-48], whilst 22% had MG coinfection [16-29].  
Relative to men with MG monoinfection, those with chlamydial monoinfection reported 
more anal pain (adjusted prevalence odds ratio(aPOR) 4.68, [1.41-14.19]), while men with 
gonococcal monoinfection reported more anal pain (aPOR 6.75, [2.21-20.55]) and tenesmus 
(aPOR 15.44, [1.62-146.90]), but less anal itch (aPOR 0.32, [0.11-0.93]).  The 
microbiological cure for MG using azithromycin was low at 35% [22-50], while 
moxifloxacin subsequently cured 92% [64-100], and pristinamycin 79% [54-94] of infections. 
Conclusion 
MG was almost as common as chlamydia in men presenting to a sexual health centre with 
symptoms of proctitis.  Men with anorectal MG monoinfection were less likely to have 
symptoms and signs compared to those with chlamydia or gonococcus monoinfection.  Cure 
for men with symptomatic anorectal MG by azithromycin was low.  We suggest routine 
testing for MG in cases of proctitis, with test of cure following treatment being essential.  
Key words: Mycoplasma genitalium, men who have sex with men, proctitis, Chlamydia 
trachomatis, Neisseria gonorrhoea 
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INTRODUCTION 
Mycoplasma genitalium (MG) is a sexually transmitted infection (STI), and has recently been 
implicated in lower and upper reproductive tract disease in women, and non-gonococcal 
urethritis in men(1, 2).  However, less is known about its prevalence and contribution to 
anorectal symptoms in men who have sex with men (MSM).  Melbourne Sexual Health 
Centre (MSHC) has reported a significant increase in MG positivity in anal swabs from 
MSM, from 2.5% in 2009 to 12.7% in 2014 (p-trend=0.005), which was not the case for 
urine and urethral samples(3).  However, a limitation of that study was that the anal samples 
were from men regardless of symptoms, so it was not clear what proportion were from men 
who had symptoms of proctitis or from an asymptomatic contact of MG.  A smaller MSHC 
study examining aetiological agents of proctitis between 2012 and 2013 that included 21% 
HIV-positive men, reported that 12% of cases had detectable MG(4): however, the study did 
not provide information on the clinical presentation of MG proctitis compared to other 
aetiological agents.  A Ugandan study reported the clinical presentation of urogenital MG 
may differ from other aetiological agents(5), but we are unaware of data on the clinical 
characteristics of MG-positive proctitis. 
 
No STI guidelines recommend a treatment regimen specifically for MG-positive proctitis(6-
8) with treatment based on current recommendations for urogenital MG infections(9).  
Increasing macrolide resistance for urogenital MG is reported and a recent meta-analysis of 
urogenital MG showed that the pooled cure for azithromycin in studies before 2009 was 85% 
(95% confidence interval (CI):82-88) declining to 67% (95% CI: 57-77)(10) in studies after 
2009.  Importantly, these data did not include anorectal MG and were largely studies of 
heterosexual men.  In Melbourne, three consecutive studies reported declining cure rates for 
MG following azithromycin over the last decade: 85% (95% CI: 77-90) in 2005-2007(11), 
69% (95% CI: 60-80) in 2008-2011(12), and 61% (95% CI: 53-69) in 2012-13(13).  These 
studies were dominated by urogenital MG with very few anorectal cases.   
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In this study, we report the clinical characteristics associated with proctitis in MSM attending 
MSHC between 2012 and 2016 in whom MG was detected and to compare this with the 
characteristics associated with the most established causes of proctitis, chlamydial and 
gonococcal proctitis.  We also compared the group of men who tested positive to MG and 
had other coinfections to examine the effect of MG alone (i.e. whether there were differences 
between Mg monoinfection and Mg coinfection).  We report the proportions cured with first 
line (azithromycin) and second-line antimicrobials (moxifloxacin, pristinamycin).  To date, 
there has not been any published data for antimicrobials such as moxifloxacin and 
pristinamycin for management of anorectal MG, so we provide the first data for these two 
agents. 
 
METHODS: 
Study participants 
We obtained routinely collected data from MSHC’s electronic medical record database of 
patients diagnosed with proctitis who were tested for all three pathogens (Mycoplasma 
genitalium, Chlamydia trachomatis and Neisseria gonorrhoeae) and had at least one 
detected.  We included MSM aged 18 years and over, who attended MSHC from June 2012 
to May 2016.  MSM status was self-reported at registration as someone who ever had any 
oral or anal sex with another man.  To avoid duplication of detecting persistent infection, we 
excluded men who presented with proctitis who had had the same organism detected within 
the previous 6 months.  All cases included in the study were single episodes of proctitis. 
 
Measurement 
Demographic data were collected including patient’s age, HIV serostatus, whether they had a 
current regular partner, the number of casual partners in the last 3 and 12 months, and any 
condomless receptive anal sex within the last 3 and 12 months.  Clinical data collected 
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included patient symptoms, the duration (anal pain, anal discharge, anal bleeding, anal itch, 
tenesmus) and clinical signs (inguinal lymphadenopathy, anal bleeding, discharge and/or 
ulceration).   
 
Proctitis was a clinical diagnosis made by the clinician, defined as anal pain with or without 
discharge and bleeding on examination.  Proctoscopy was discretionary, performed in a 
subset of males (36%) in keeping with clinic practice due to poor tolerability in symptomatic 
patients and with increasing use of highly sensitive nucleic acid amplification testing 
(NAAT) where direct visualization and sampling from inflamed mucosa is not required.  
From June 2012, clinic guidelines recommended all men who presented to MSHC with 
proctitis have anal swabs to test for C. trachomatis (CT), N. gonorrhoeae (NG), and M. 
genitalium.  Testing for Treponema pallidum and herpes simplex virus (HSV) was performed 
at clinician’s discretion.  MG testing was performed at the Molecular Microbiology 
Laboratory at the Royal Women’s Hospital using an in-house real-time polymerase chain 
reaction (PCR) assay targeting the 16s rRNA gene(14).  Before March 2015, chlamydia was 
detected using strand displacement amplification (BD Probetec) and gonorrhoea was detected 
by culture on modified Thayer Martin medium.  After March 2015, chlamydia and 
gonorrhoea were detected using the APTIMA Combo 2 assay (GenProbe Diagnostics)(15).  
All positive gonorrhoea results were confirmed using the Aptima GC test (Gen-Probe 
Diagnostics, San Diego, California)(16), which uses a different nucleic acid target.  When 
chlamydia was detected, genotyping for LGV was performed using previously published 
methods with minor modifications(17).  The equivalent serovar was identified by finding the 
closest matching nucleotide sequence of L2 and L2b from Genebank no. M14738 and 
AY586530.  HSV detection was by PCR targeting the glycoprotein B gene using 
conventional PCR and a real-time version of this(18).  Treponema pallidum was tested using 
a TaqMan real-time PCR assay(19). 
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Statistical analysis 
We stratified the demographic and sexual behaviour data by monoinfection with MG, 
chlamydia, or gonorrhoea, and coinfection of MG with other STIs (this included NG, CT, 
LGV, HSV and syphilis, and will henceforth be referred to as ‘MG coinfection’).  We 
excluded from further analysis, men who did not have rectal MG and had two or more other 
rectal STIs.  To assess for statistically significant differences, we used Fisher’s exact test for 
categorical data and Kruskal-Wallis test for non-parametric continuous data.  We conducted a 
multinomial multivariable logistic regression to test for significant differences between 
specific clinical features of proctitis caused by different aetiological agents.  The dependent 
variable was categorized into four different groups: MG monoinfection (reference group), 
chlamydial monoinfection, gonococcal monoinfection, and MG coinfection.  This was 
adjusted for age, HIV status and condomless receptive anal sex in the last 3 months.  
Prevalence odds ratios were calculated with the level of statistical significance at p<0.05.  
Successful treatment outcomes were identified as men who had a repeat negative test for MG 
at least two weeks after treatment with first line (azithromycin) or second line (moxifloxacin 
or pristinamycin) antimicrobials.  Men were routinely recalled for their test of cure.  All 
analyses were conducted using STATA software version 13.1 (StataCorp, College Station, 
TX, USA). 
 
Ethical approval was obtained from the Alfred Human Research Ethics Committee (308/16). 
 
RESULTS 
Study population 
During the study period, 201 MSM with 212 episodes of proctitis were tested for the three 
STIs: M. genitalium, C. trachomatis and N. gonorrhoeae.  Cases were tested for anorectal 
herpes in 82% (174/212), anorectal syphilis using NAAT in 57% (121/212) and, of the men 
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with anorectal chlamydia, 68% (54/80) were tested for anorectal LGV.  The most prevalent 
agent detected in cases with symptoms of proctitis was gonorrhoea (54%, 95% confidence 
interval [47-61], followed by chlamydia (38% [31-45]) and MG (31% [25-38]).  LGV was 
detected in 4% (2/54) of men whose positive chlamydia anal swab was also tested for LGV 
strains. 
 
For further analysis describing clinical features of proctitis, we excluded cases who had two 
or more other rectal STIs but no MG(n=46).  Therefore, we retained for analysis 
monoinfection cases with MG (17%, [12-24], 29/166), chlamydia (20%, [15-27], 34/166), 
gonorrhoea (40%, [32-48], 66/166), and MG coinfection (22%, [16-29], 37/166).  Men with 
MG coinfection had: herpes (38%, [22-55], 14/37), gonorrhoea (27%, [14-44], 10/37), 
chlamydia (27%, [14-44], 10/37), syphilis (22%, [10-38], 8/37), and LGV (5%, [1-18], 2/37) 
detected.  Seven men had three concurrent pathogens. 
 
The demographic characteristics are summarized in Table 1.  Men with Mg monoinfection 
had a higher median age (33 years), compared to those with Mg coinfection (29 years), 
chlamydial monoinfection (27 years) and gonococcal monoinfection (25 years) (P<0.001).  
Men with MG monoinfection had less condomless receptive anal sex within the last 3 months 
(52%) compared with chlamydial monoinfection (88%), gonococcal monoinfection (71%), 
and MG coinfection (59%)(P=0.01).  There was a higher proportion of HIV in men with MG 
monoinfection (28%) and MG coinfection (35%), compared with chlamydial monoinfection 
(12%), and gonococcal monoinfection (14%)(p=0.05). 
 
Clinical characteristics of anorectal MG 
When adjusted for age, HIV status and condomless anal sex in the last 3 months, relative to 
men with MG monoinfection, men with chlamydial monoinfection were more likely to report 
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anal pain (adjusted prevalence odds ratio (aPOR) 4.68 [1.41-14.19]), Table 2.  Men with 
gonococcal monoinfection were more likely to report both anal pain (aPOR 6.75 [2.21-20.55]) 
and tenesmus (aPOR 15.44 [1.62-146.90]), but were less likely to report anal itch (aPOR 0.32 
[0.11-0.93]).  Men with MG coinfection were more likely to report anal pain (aPOR 4.45 
[1.39-14.19]) and anal ulceration (RRR 4.27 [1.02-17.73]) compared to men with MG 
monoinfection; however 38% of MG coinfected cases had HSV.   
 
Treatment outcomes 
The majority of cases with MG returned for a test of cure (77%, 51/66).  All cases who 
returned for a test of cure received azithromycin first line and the overall proportion with 
microbiological cure was low at 35% (95% CI:22-50, 18/51).  Thirteen cases had 
moxifloxacin as a second-line antimicrobial with an overall microbiological cure proportion 
of 92% (95% CI:64-100, 12/13).  Twenty-one cases received pristinamycin as a second-line 
antimicrobial with an overall microbiological cure of 79% (95% CI:54-94, 15/19). 
 
DISCUSSION 
This study of MSM attending a sexual health centre in Melbourne, Australia, investigated the 
clinical features of proctitis in which Mycoplasma genitalium was detected, and reported 
susceptibility to first- and second-line antimicrobials.  It adds to the limited literature on 
anorectal MG-infection by reporting that anorectal MG was as common as chlamydia in 
MSM presenting with symptoms of proctitis.  However, MG proctitis was associated with 
fewer symptoms, indicative of lesser clinical severity of inflammation compared to cases of 
chlamydia or gonorrhoea detected as the sole pathogen.  Of concern but not unexpectedly, as 
with urethral infections the majority of MG-positive proctitis was not susceptible to 
macrolides. 
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We contribute several important observations regarding anorectal MG in MSM.  First, MG 
appears likely to be a causative agent of proctitis.  It is possible that MG may be incidentally 
detected in men presenting with symptoms of proctitis as untreated urogenital MG may last 
for months or years(20).  However, against incidental detection is the fact that we found a 
significant difference in the anorectal MG prevalence between men with asymptomatic MG 
infection attending MSHC in another study compared to men with symptomatic MG.  In an 
ongoing study at our service, 401 asymptomatic MSM were tested for anorectal MG and MG 
was detected in 5.0% (95% CI: 3.1, 7.6)(21).  In support of MG causing symptomatic 
anorectal infection, we found six-fold higher positivity of anorectal MG amongst cases 
presenting with proctitis, compared to this background prevalence in asymptomatic MSM(21).   
 
Second, consistent with research in pelvic inflammatory disease(22), our findings suggests 
that MG may be less inflammatory compared to Chlamydia trachomatis and Neisseria 
gonorrhoea, indicating MG may be a more indolent infection in men and women(23).  
Previous literature has been conflicting regarding the association between MG and 
symptomatic anorectal infection.  This may be partly influenced by patient selection and the 
health seeking patterns across populations.  In a small study from USA of 27 MSM with 
anorectal MG, investigators reported that rectal symptoms (rectal pain, bleeding, discharge or 
tenesmus) were moderately associated with rectal MG detection (OR 2.8, 95% CI: 1.0-
8.0)(24).  However, they did not report the duration of symptoms nor stratify their analysis 
according to specific symptoms.  Conversely, in another small study from the UK of 19 
MSM with anorectal MG, no associations were found between MG and symptoms of 
proctitis(25).  This difference may either be explained by their small sample size or that 
bacterial load of MG may influence symptoms for both urethral and anorectal MG(4, 26). It 
is noteworthy that men presenting with symptomatic anorectal NG had higher bacterial loads 
compared to men with anorectal NG but without any rectal symptoms(27).  
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Not unexpectedly, the majority of infections with MG proctitis were not susceptible to the 
first-line treatment of azithromycin.  This is consistent with published evidence showing 
rising resistance in urogenital MG infections globally(28).  Further, recent MSHC data in 
asymptomatic MSM confirms 90% (95% CI: 68, 99) of men with anorectal MG had 
macrolide resistance(21).  The overall cure of symptomatic anorectal MG with subsequent 
antimicrobials (moxifloxacin, pristinamycin) was consistent with the cure rates of 88% cure 
reported for moxifloxacin and 75% cure reported for pristinamycin found in urogenital 
MG(13, 29).  To the best of our knowledge, this is the first published data on the use of these 
agents for anorectal MG infection.  These data indicate similar overall efficacy of the three 
antimicrobials for anorectal infection, as is reported for urogenital infection, but highlight the 
need for use of combined diagnostic resistance assays to facilitate selection of appropriate 
antimicrobials at the time of diagnosis and routine test of cure(30).   
 
The strength of the study includes using a relatively large database of MSM with symptoms 
of proctitis, who were also comprehensively tested for other STIs.  The majority of men 
returned for a test of cure for MG, enabling us to report the proportion of microbiological 
cure in men receiving various antimicrobials.  This study should be read in light of some 
limitations.  First, we did not perform proctoscopy in the majority of cases, as this is an 
uncomfortable procedure of doubtful clinical value now that we have sensitive diagnostic 
tests that do not require direct visualization for collection.  Second, gonococcal cases were 
predominantly culture positive and therefore likely to represent high bacterial load infections 
which may bias our results towards more symptoms being associated with anorectal GC.  
Finally, we do not have contemporaneous data on the prevalence of MG in asymptomatic 
controls, which would enable us to establish an association between MG and proctitis, 
although an association appears likely from the our recent asymptomatic prevalence study 
mentioned(21). 
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In conclusion, current international STI guidelines do not have clear recommendations for 
testing and treatment of MG in men presenting with proctitis(6-8).  This study found that MG 
was almost as common as chlamydia in men presenting to a sexual health centre with 
symptoms of proctitis but appears to be associated with less marked symptoms than 
chlamydia and gonorrhoea.  These data are consistent with the evidence supporting the role 
of MG in PID, where it has taken many years to establish an association with PID.  Symptom 
severity suggestive of anorectal inflammation appears to be very similar between the three 
STIs in PID and proctitis with MG seemingly the more indolent STI in both clinical 
syndromes.  Based on the findings of this study we recommend: i) testing for MG in men 
presenting with symptoms of proctitis, ii) use of combined diagnostic-resistance assays to 
facilitate early selection of appropriate antimicrobials and iii) routine test of cure following 
antimicrobials.  Cure following moxifloxacin and pristinamycin appears to be in line with 
that reported for urogenital MG.  These data highlight the fact that MG is a relevant STI in 
MSM.   
 
Author contribution: JJO, CB, and TRHR contributed to the conception and design of the 
study. JJO and EA collected the data.  JJO analysed the data and drafted the paper.  All 
authors revised the manuscript and approved the final version to be published.   
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Table 1 Demographics of cases with MG monoinfection, chlamydial monoinfection, gonococcal monoinfection and MG coinfection, 
Melbourne Sexual Health Centre (2012-2016), N=166. 
Variable MG monoinfection  
(N=29) 
n (%) or median [IQR] 
Chlamydial 
monoinfection (N=34) 
n (%) or median [IQR] 
Gonococcal 
monoinfection (N=66) 
n (%) or median (IQR) 
MG coinfection 
(N=37) 
n (%) or median [IQR] 
P value 
Age (years) 33 [28-38] 27 [24-33] 25 [22-31] 29 [26-33] <0.001 
HIV-positive 8 (28) 4 (12) 9 (14) 13 (35) 0.05 
Had a current regular partner 13 (45) 11 (32) 27 (41) 8 (22) 0.22 
Number of casual partners in the last 12 months 5 [3-10] 8 [5-15] 6 [3-12] 10 [5-25] 0.29 
Number of casual partners in the last 3 months 2 [1-4] 4 [3-6] 3 [1-6] 3 [2-5] 0.25 
Condomless receptive anal sex in the last 3 months 15 (52) 30 (88) 47 (71) 22 (59) 0.01 
IQR = interquartile range 
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Table 2 Characteristics associated with proctitis in which MG was detected as the sole pathogen compared to chlamydial monoinfection, 
gonococcal monoinfection and MG coinfection, Melbourne Sexual Health Centre (2012-2016), N=166  
Characteristic Chlamydial monoinfection 
vs. MG monoinfection  
Adjusted POR
#
 (95% CI) 
P value Gonococcal monoinfection 
vs. MG monoinfection  
Adjusted POR
#
 (95% CI) 
P value MG coinfection vs.  
MG monoinfection  
Adjusted POR
#
 (95% CI) 
P value 
Symptoms       
- Anal pain 4.68 (1.41-14.19)* 0.01 6.75 (2.21-20.55) <0.01 4.45 (1.39-14.19)* 0.01 
- Anal pain duration (per additional day) 1.00 (0.99-1.02) 0.62 0.97 (0.93-1.01) 0.13 0.99 (0.98-1.01) 0.48 
- Anal discharge 0.89 (0.29-2.73) 0.85 2.02 (0.75-5.48) 0.17 1.19 (0.41-3.44) 0.74 
- Anal discharge duration (per additional day) 1.00 (0.96-1.03) 0.79 0.96 (0.90-1.02) 0.17 0.94 (0.85-1.03) 0.17 
- Anal bleeding 1.07 (0.35-3.31) 0.91 0.71 (0.25-2.03) 0.52 0.64 (0.21-2.00) 0.45 
- Anal bleeding duration (per additional day) 0.99 (0.98-1.01) 0.52 0.93 (0.87-1.00) 0.06 0.92 (0.83-1.03) 0.15 
- Anal itch 0.52 (0.16-1.64) 0.26 0.32 (0.11-0.93)* 0.04 0.50 (0.17-1.50) 0.22 
- Anal itch duration (per additional day) 1.09 (0.92-1.29) 0.31 0.81 (0.60-1.07) 0.14 1.09 (0.93-1.29) 0.30 
- Tenesmus 4.24 (0.37-49.06) 0.25 15.44 (1.62-146.90)* 0.02 6.10 (0.60-62.08) 0.13 
- Tenesmus duration (per additional day) 0.77 (0.43-1.38) 0.38 1.13 (0.73-1.73) 0.59 0.88 (0.55-1.41) 0.60 
Examination findings       
- Anal discharge 2.49 (0.43-14.50) 0.31 3.93 (0.79-19.55) 0.10 3.17 (0.58-17.31) 0.18 
- Inguinal lymphadenopathy
$
 - - - - - - 
- Anal bleeding
$
 - - - - - - 
- Anal ulcer 0.49 (0.07-3.35) 0.47 0.69 (0.15-3.28) 0.65 4.27 (1.02-17.73)* 0.04 
#
 multinomial multivariate logistic regression analysis adjusted for age, HIV status and condomless receptive anal sex in the last 3 months; * p<0.05, ** p<0.01; 
$ 
Too few 
cases with variability for inguinal lymphadenopathy and anal bleeding to calculate an adjusted POR; POR= Prevalence odds ratio, 95% CI = 95% confidence interval 
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